Literature DB >> 25807434

Epidemiology of prostate cancer: current status.

Z-Q Tao1, A-M Shi, K-X Wang, W-D Zhang.   

Abstract

Prostate cancer is one of the most common cancers affecting men with > 1,100,000 new cases and 300,000 deaths worldwide each year. The disease is more common among older men, with a median age at diagnosis around age above 60 years. Prostate cancer is a major medical problem that needs immediate attention as the disease is indolent, shows prolonged latency in association with high morbidity and mortality. Administration of diagnostic tests including PSA test and biopsies and the advances in other diagnostic procedures have led to early detection of the disease with therapeutic steps being taken early on, there has been a steady decline in the disease-specific mortality. Global incidence and mortality rates show that the disease is more prevalent among black people, even though the differences cannot be attributed entirely to race, as the influence of socioeconomic situation and the resultant limited access to medical technologies and treatment could not be ruled out completely. Several genes have been identified that when mutated confer high risk for the disease. Besides the genetic factors, family history and nutritional factors such as lack of enough vitamin D, high intake of calcium, obesity and high fat diets have been implicated as risk factors for prostate cancer. Therapeutic measures for prostate cancer involve mostly radical prostatectomy followed by radiotherapy in combination with hormonal treatment as needed.

Entities:  

Mesh:

Year:  2015        PMID: 25807434

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  28 in total

1.  The level of knowledge and awareness about prostate cancer in the Turkish male and the relevant effective factors.

Authors:  Sadi Turkan; Faruk Doğan; Ozan Ekmekçioğlu; Aslıhan Çolak; Mehmet Kalkan; Çoşkun Şahin
Journal:  Turk J Urol       Date:  2016-09

2.  Does race predict the development of metastases in men who receive androgen-deprivation therapy for a biochemical recurrence after radical prostatectomy?

Authors:  Adriana C Vidal; Lauren E Howard; Amanda De Hoedt; Christopher J Kane; Martha K Terris; William J Aronson; Matthew R Cooperberg; Christopher L Amling; Stanislav Lechpammer; Scott C Flanders; Stephen J Freedland
Journal:  Cancer       Date:  2018-11-14       Impact factor: 6.860

3.  Trends in the incidence rate of genitourinary system cancers in Turkey: 2004-2015.

Authors:  Pakize Yiğit; Ömer Ataç; Sabahattin Aydın
Journal:  Turk J Urol       Date:  2020-03-27

4.  [Identification and validation of hub genes in prostate cancer progression based on weighted gene co-expression network analysis].

Authors:  H Zhang; N Chen; X Wang; B Gao; M Ling; G Chen; Z Wu; Y Li; W Zhong; B Pan
Journal:  Nan Fang Yi Ke Da Xue Xue Bao       Date:  2021-11-20

5.  Urotensin II receptor on preoperative biopsy is associated with upstaging and upgrading in prostate cancer.

Authors:  Ottavio De Cobelli; Carlo Buonerba; Daniela Terracciano; Danilo Bottero; Giuseppe Lucarelli; Pierluigi Bove; Vincenzo Altieri; Ioman Coman; Sisto Perdonà; Gaetano Facchini; Massimiliano Berretta; Giuseppe Di Lorenzo; Paolo Grieco; Ettore Novellino; Renato Franco; Michele Caraglia; Claudia Manini; Vincenzo Mirone; Sabino De Placido; Guru Sonpavde; Matteo Ferro
Journal:  Future Oncol       Date:  2015-09-18       Impact factor: 3.404

Review 6.  Prostate Cancer Prevention: Concepts and Clinical Trials.

Authors:  Zachary Hamilton; J Kellogg Parsons
Journal:  Curr Urol Rep       Date:  2016-04       Impact factor: 3.092

7.  New study suggests patients with advanced prostate cancer on androgen deprivation therapy need more dialogue with health care provider, especially around cardiovascular risk.

Authors:  Axel Merseburger; Anne Bro Falkenberg; Olga J Kornilova
Journal:  World J Urol       Date:  2018-09-22       Impact factor: 4.226

8.  Hypoxia-Responsive Mir-301a and Mir-301b Promote Radioresistance of Prostate Cancer Cells via Downregulating NDRG2.

Authors:  Wei Wang; Mingbo Liu; Yawei Guan; Qingwu Wu
Journal:  Med Sci Monit       Date:  2016-06-21

9.  MicroRNA-410-5p as a potential serum biomarker for the diagnosis of prostate cancer.

Authors:  Jiaqi Wang; Huamao Ye; Dandan Zhang; Yijun Hu; Xiya Yu; Long Wang; Changjing Zuo; Yongwei Yu; Guixia Xu; Shanrong Liu
Journal:  Cancer Cell Int       Date:  2016-02-19       Impact factor: 5.722

10.  Methylation pattern analysis in prostate cancer tissue: identification of biomarkers using an MS-MLPA approach.

Authors:  Giorgia Gurioli; Samanta Salvi; Filippo Martignano; Flavia Foca; Roberta Gunelli; Matteo Costantini; Giacomo Cicchetti; Ugo De Giorgi; Persio Dello Sbarba; Daniele Calistri; Valentina Casadio
Journal:  J Transl Med       Date:  2016-08-30       Impact factor: 8.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.